5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Thrombotic microangiopathy in children

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The syndrome of thrombotic microangiopathy (TMA) is a clinical-pathological entity characterized by microangiopathic hemolytic anemia, thrombocytopenia, and end organ involvement. It comprises a spectrum of underlying etiologies that may differ in children and adults. In children, apart from ruling out shigatoxin-associated hemolytic uremic syndrome (HUS) and other infection-associated TMA like Streptococcus pneumoniae-HUS, rare inherited causes including complement-associated HUS, cobalamin defects, and mutations in diacylglycerol kinase epsilon gene must be investigated. TMA should also be considered in the setting of solid organ or hematopoietic stem cell transplantation. In this review, acquired and inherited causes of TMA are described with a focus on particularities of the main causes of TMA in children. A pragmatic approach that may help the clinician tailor evaluation and management is provided. The described approach will allow for early initiation of treatment while waiting for the definitive diagnosis of the underlying TMA.

          Related collections

          Most cited references92

          • Record: found
          • Abstract: found
          • Article: not found

          Syndromes of thrombotic microangiopathy.

          This review article covers the diverse pathophysiological pathways that can lead to microangiopathic hemolytic anemia and a procoagulant state with or without damage to the kidneys and other organs.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue.

            The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA) Special Issue Writing Committee is charged with reviewing, updating and categorizing indications for the evidence-based use of therapeutic apheresis (TA) in human disease. Since the 2007 JCA Special Issue (Fourth Edition), the committee has incorporated systematic review and evidence-based approaches in the grading and categorization of apheresis indications. This Eighth Edition of the JCA Special Issue continues to maintain this methodology and rigor in order to make recommendations on the use of apheresis in a wide variety of diseases/conditions. The JCA Eighth Edition, like its predecessor, continues to apply the category and grading system definitions in fact sheets. The general layout and concept of a fact sheet that was introduced in the Fourth Edition, has largely been maintained in this edition. Each fact sheet succinctly summarizes the evidence for the use of TA in a specific disease entity or medical condition. The Eighth Edition comprises 84 fact sheets for relevant diseases and medical conditions, with 157 graded and categorized indications and/or TA modalities. The Eighth Edition of the JCA Special Issue seeks to continue to serve as a key resource that guides the utilization of TA in the treatment of human disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

              In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von Willebrand factor-cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis, which result in thrombocytopenia, hemolytic anemia, and tissue ischemia. Caplacizumab, an anti-von Willebrand factor humanized, bivalent variable-domain-only immunoglobulin fragment, inhibits interaction between von Willebrand factor multimers and platelets.
                Bookmark

                Author and article information

                Contributors
                lilianp@unicamp.br
                Journal
                Pediatr Nephrol
                Pediatr Nephrol
                Pediatric Nephrology (Berlin, Germany)
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0931-041X
                1432-198X
                18 January 2022
                : 1-14
                Affiliations
                [1 ]GRID grid.411087.b, ISNI 0000 0001 0723 2494, Department of Pediatrics, Pediatric Nephrology, , State University of Campinas (UNICAMP), Rua Tessalia Vieira de Camargo, ; 126, Cidade Universitaria, Campinas, SP 13,083–887 Brazil
                [2 ]GRID grid.410543.7, ISNI 0000 0001 2188 478X, Pediatric Nephrology, , State University of São Paulo (USP), ; São Paulo, Brazil
                [3 ]GRID grid.66875.3a, ISNI 0000 0004 0459 167X, Hematology, Department of Internal Medicine, , Mayo Clinic, ; Rochester, MN USA
                [4 ]GRID grid.66875.3a, ISNI 0000 0004 0459 167X, Pediatric Nephrology, Department of Pediatrics, , Mayo Clinic, ; Rochester, MN USA
                [5 ]GRID grid.66875.3a, ISNI 0000 0004 0459 167X, Department of Laboratory Medicine and Pathology, , Mayo Clinic, ; Rochester, MN USA
                Author information
                http://orcid.org/0000-0002-4536-7709
                Article
                5370
                10.1007/s00467-021-05370-8
                8764494
                35041041
                edb25062-afba-44ff-b428-95d982b2a45b
                © The Author(s), under exclusive licence to International Pediatric Nephrology Association 2022

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 30 September 2021
                : 12 November 2021
                : 15 November 2021
                Categories
                Review

                Nephrology
                thrombotic microangiopathy,complement,dgke,hypertension,infection,hemolytic uremic syndrome,transplant

                Comments

                Comment on this article